[1] R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer Statistics, 2021, CA: a cancer journal for clinicians 71(1) (2021) 7-33. https://doi.org/10.3322/caac.21654.
[2] S.B. Clark, S. Alsubait, Non Small Cell Lung Cancer, StatPearls, StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC., Treasure Island (FL), 2021.https://www.ncbi.nlm.nih.gov/books/NBK562307.
[3] B.C. Bade, C.S. Dela Cruz, Lung Cancer 2020: Epidemiology, Etiology, and Prevention, Clinics in chest medicine 41(1) (2020) 1-24. https://doi.org/10.1016/j.ccm.2019.10.001.
[4] N.A. Thomas, N.T. Tanner, Lung Cancer Screening: Patient Selection and Implementation, Clinics in Chest Medicine 41(1) (2020) 87-97. https://doi.org/10.1016/j.ccm.2019.10.006.
[5] R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer Statistics, 2021, CA: a cancer journal for clinicians 71(1) (2021) 7-33. https://doi.org/10.3322/caac.21654.
[6] G. Sartori, L. Belluomini, F. Lombardo, A. Avancini, I. Trestini, E. Vita, D. Tregnago, J. Menis, E. Bria, M. Milella, S. Pilotto, Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives, Expert Review of Anticancer Therapy 20(7) (2020) 531-542. https://doi.org/10.1080/14737140.2020.1776119.
[7] T. Asao, F. Takahashi, K. Takahashi, Resistance to molecularly targeted therapy in non-small-cell lung cancer, Respiratory Investigation 57(1) (2019) 20-26. https://doi.org/10.1016/j.resinv.2018.09.001.
[8] P.O. Bolan, A. Zviran, L. Brenan, J.S. Schiffman, N. Dusaj, A. Goodale, F. Piccioni, C.M. Johannessen, D.A. Landau, Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization, Cell Systems 10(1) (2020) 52-65.e7. https://doi.org/10.1016/j.cels.2019.10.002.
[9] M. Xiang, H.G. Jiang, Y. Shu, Y.J. Chen, J. Jin, Y.M. Zhu, M.Y. Li, J.N. Wu, J. Li, Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis, Int J Biol Sci 16(9) (2020) 1536-1550. https://doi.org/10.7150/ijbs.40042.
[10] J. Gao, H.R. Li, C. Jin, J.H. Jiang, J.Y. Ding, Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer, Clinical and Translational Oncology 21(10) (2019) 1287-1301. https://doi.org/10.1007/s12094-019-02075-1.
[11] D. Westover, J. Zugazagoitia, B.C. Cho, C.M. Lovly, L. Paz-Ares, Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors, Ann Oncol 29(suppl_1) (2018) i10-i19. https://doi.org/10.1093/annonc/mdx703.
[12] S.P. Wheatley, D.C. Altieri, Survivin at a glance, Journal of cell science 132(7) (2019). https://doi.org/10.1242/jcs.223826.
[13] F. Shojaei, F. Yazdani-Nafchi, M. Banitalebi-Dehkordi, M. Chehelgerdi, M. Khorramian-Ghahfarokhi, Trace of survivin in cancer, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 28(4) (2019) 365-372. https://doi.org/10.1097/CEJ.0000000000000453.
[14] S.S.J. W S Lin, J-T A Hsu,Shih Sheng Jiang ,Overcoming acquired resistance to BIBW2992 in HCC827, a non-small cell lung cancer cell line by dasatinib, arrayexpress-repository, V1, ( 2016).
[15] L. Girard, J. Rodriguezcanales, C. Behrens, D. Thompson, I. Botros, H. Tang, Y. Xie, N. Rekhtman, W.D. Travis, I.I. Wistuba, An expression signature as an aid to the histologic classification of non-small cell lung cancer, Clinical Cancer Research 22(19) (2016) 4880-4889. https://doi.org/10.1158/1078-0432.CCR-15-2900.
[16] A. Sanchezpalencia, M. Gomezmorales, J.A. Gomezcapilla, V. Pedraza, L. Boyero, R. Rosell, M.E. Farezvidal, Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer, International Journal of Cancer 129(2) (2011) 355-364.
https://doi.org/ 10.1002/ijc.25704.
[17] T. Barrett, S.E. Wilhite, P. Ledoux, C. Evangelista, I.F. Kim, M. Tomashevsky, K.A. Marshall, K.H. Phillippy, P.M. Sherman, M. Holko, A. Yefanov, H. Lee, N. Zhang, C.L. Robertson, N. Serova, S. Davis, A. Soboleva, NCBI GEO: Archive for functional genomics data sets - Update, Nucleic Acids Research 41(D1) (2013) D991-D995. https://doi.org/10.1093/nar/gks1193.
[18] W. Huang da, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nature protocols 4(1) (2009) 44-57. https://doi.org/10.1038/nprot.2008.211.
[19] D.R. Rhodes, S. Kalyana-Sundaram, V. Mahavisno, R. Varambally, J. Yu, B.B. Briggs, T.R. Barrette, M.J. Anstet, C. Kincead-Beal, P. Kulkarni, S. Varambally, D. Ghosh, A.M. Chinnaiyan, Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles, Neoplasia 9(2) (2007) 166-180. https://doi.org/ 10.1593/neo.07112.
[20] T. Li, J. Fan, B. Wang, N. Traugh, Q. Chen, J.S. Liu, B. Li, X.S. Liu, TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells, Cancer research 77(21) (2017) e108-e110.https://doi.org/10.1158/0008-5472.CAN-17-0307.
[21] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, Z. Zhang, GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses, Nucleic Acids Res 45(W1) (2017) W98-w102. https://doi.org/10.1093/nar/gkx247.
[22] A. Lánczky, Á. Nagy, G. Bottai, G. Munkácsy, A. Szabó, L. Santarpia, B. Győrffy, miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients, Breast cancer research and treatment 160(3) (2016) 439-446. https:// 10.1007/s10549-016-4013-7.
[23] D. Warde-Farley, S.L. Donaldson, O. Comes, K. Zuberi, R. Badrawi, P. Chao, M. Franz, C. Grouios, F. Kazi, C.T. Lopes, A. Maitland, S. Mostafavi, J. Montojo, Q. Shao, G. Wright, G.D. Bader, Q. Morris, The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function, Nucleic Acids Research 38(suppl_2) (2010) W214-W220. https://doi.org/10.1093/nar/gkq537.
[24] A. Benito-Martin, H. Peinado, FunRich proteomics software analysis, let the fun begin!, PROTEOMICS 15(15) (2015) 2555-2556. https:// 10.1002/pmic.201500260.
[25] N.K. Lytle, A.G. Barber, T.J.N.R.C. Reya, Stem cell fate in cancer growth, progression and therapy resistance, 18(11) (2018) 669-680. https://doi.org/10.1038/s41568-018-0056-x.
[26] Z.F. Lim, P.C. Ma, Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy, Journal of hematology & oncology 12(1) (2019) 134. https:// doi.org/ 10.1186/s13045-019-0818-2.
[27] M. Haschka, G. Karbon, L.L. Fava, A. Villunger, Perturbing mitosis for anti-cancer therapy: is cell death the only answer?, EMBO reports 19(3) (2018). https:// doi.org/10.15252/embr.201745440.
[28] C. Buccitelli, M. Selbach, mRNAs, proteins and the emerging principles of gene expression control, Nature Reviews Genetics 21(10) (2020) 630-644. https:// doi.org/10.1038/s41576-020-0258-4.
[29] J. Han, L.A. Goldstein, W. Hou, S. Chatterjee, T.F. Burns, H. Rabinowich, HSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC, Autophagy 14(6) (2018) 958-971. https:// doi.org/10.1080/15548627.2018.1434471.
[30] J. Bertranalamillo, V. Cattan, M. Schoumacher, J. Codonyservat, A. Gimenezcapitan, F. Cantero, M.F. Burbridge, S. Rodriguez, C. Teixido, R.J.N.C. Roman, AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy, 10(1) (2019) 1812. https://doi.org/10.1038/s41467-019-09734-5.
[31] K.N. Shah, R. Bhatt, J. Rotow, J. Rohrberg, V. Olivas, V. Wang, G. Hemmati, M.M. Martins, A. Maynard, J.J.N.M. Kuhn, Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer, 25(1) (2019) 111-118. https://doi.org/10.1038/s41591-018-0264-7.
[32] P. Khongkow, A.R. Gomes, C. Gong, E.P.S. Man, J.W.H. Tsang, F. Zhao, L.J. Monteiro, R.C. Coombes, R.H. Medema, U.S.J.O. Khoo, Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance, 35(8) (2016) 990-1002. https://doi.org/ 10.1038/onc.2015.152.
[33] B. Zhao, J. Zhang, X. Chen, H. Xu, B.J.A.o.M.S. Huang, Mir-26b inhibits growth and resistance to paclitaxel chemotherapy by silencing the CDC6 gene in gastric cancer, 15(2) (2019) 498-503. https://doi.org/ 10.5114/aoms.2018.73315.
[34] J.A. Hellyer, H. Stehr, M. Das, S.K. Padda, K. Ramchandran, J.W. Neal, M. Diehn, H.A.J.L.C. Wakelee, Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer, 134 (2019) 42-45. https://doi.org/ 10.1016/j.lungcan.2019.05.002.
[35] R. Niu, Y. Tang, Y. Xi, D.J.J.o.S.R. Jiang, High Expression of Krüppel-like Factor 7 Indicates Unfavorable Clinical Outcomes in Patients with Lung Adenocarcinoma, 250 (2020) 216-223. https://doi.org/10.1016/j.jss.2019.12.053.
[36] Y. An, Y. Shang, Z. Xu, Q. Zhang, Z. Wang, W. Xuan, X.J.B. Zhang, Pharmacotherapy, STAT3-induced long noncoding RNA LINC00668 promotes migration and invasion of non-small cell lung cancer via the miR-193a/KLF7 axis, 116 (2019) 109023. https://doi.org/10.1016/j.biopha.2019.109023.
[37] W.-j. Liu, Y. Du, R. Wen, M. Yang, J. Xu, Drug resistance to targeted therapeutic strategies in non-small cell lung cancer, Pharmacology & Therapeutics 206 (2020) 107438. https://doi.org/10.1016/j.pharmthera.2019.107438.
[38] S. Kohsaka, M. Petronczki, F. Solca, M.J.F.O. Maemondo, Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing, 15(6) (2019) 637-652. https://doi.org/10.2217/fon-2018-0736.
[39] T. Ito, Y. Kumagai, K. Itano, T. Maruyama, K. Tamura, S. Kawasaki, T. Suzuki, Y. Murakami, Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification, Biochemical and Biophysical Research Communications 511(3) (2019) 544-550. https://doi.org/10.1016/j.bbrc.2019.02.086.
[40] D. Westover, J. Zugazagoitia, B.C. Cho, C.M. Lovly, L. Paz-Ares, Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors, Ann Oncol 29(suppl_1) (2018) i10-i19. https://doi.org/10.1093/annonc/mdx703.
[41] M. Metzenmacher, D.C. Christoph, Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer, Journal of Thoracic Disease; Vol 8, No 10 (October 2016): Journal of Thoracic Disease (2016). https://doi.org/10.21037/jtd.2016.10.26.
[42] B. Ricciuti, S. Baglivo, A. De Giglio, R.J.T.A.i.R.D. Chiari, Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience, 12 (2018) 1753466618808659. https://doi.org/ 10.1177/1753466618808659.
[43] D. Westover, J. Zugazagoitia, B.C. Cho, C.M. Lovly, L.J.A.o.O. Pazares, Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors, 29 (2018). https://doi.org/ 10.1093/annonc/mdx703.
[44] F. Nasim, B.F. Sabath, G.A. Eapen, Lung Cancer, The Medical clinics of North America 103(3) (2019) 463-473. https://doi.org/ 10.1016/j.mcna.2018.12.006.
[45] R. Arafeh, Y. Samuels, PIK3CA in cancer: The past 30 years, Seminars in Cancer Biology 59 (2019) 36-49. https://doi.org/10.1016/j.semcancer.2019.02.002.
[46] S.P. Wheatley, D.C. Altieri, Survivin at a glance, Journal of cell science 132(7) (2019) jcs223826. https://doi.org/10.1242/jcs.223826.
[47] G. Zhao, Q. Wang, Z. Wu, X. Tian, H. Yan, B. Wang, P. Dong, H. Watari, L.M. Pfeffer, Y. Guo, W. Li, J. Yue, Ovarian primary and metastatic tumors suppressed by survivin knockout or a novel survivin inhibitor, Molecular Cancer Therapeutics 18(12) (2019) 2233-2245. https://doi.org/10.1158/1535-7163.MCT-19-0118.
[48] S.P. Wheatley, D.C.J.J.o.C.S. Altieri, Survivin at a glance, 132(7) (2019). https://doi.org/10.1242/jcs.223826.
[49] T. Shimizu, K. Nishio, K. Sakai, I. Okamoto, K. Okamoto, M. Takeda, M. Morishita, K. Nakagawa, Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer, Cancer Chemother Pharmacol 86(2) (2020) 211-219. https://doi.org/10.1007/s00280-020-04112-1.
[50] R.C. Peery, J.-Y. Liu, J.-T. Zhang, Targeting survivin for therapeutic discovery: past, present, and future promises, Drug Discovery Today 22(10) (2017) 1466-1477. https://doi.org/10.1016/j.drudis.2017.05.009.
[51] F. Li, I. Aljahdali, X. Ling, Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?, Journal of Experimental & Clinical Cancer Research 38(1) (2019) 368. https://doi.org/10.1186/s13046-019-1362-1.
[52] M. De Donato, G. Babini, S. Mozzetti, M. Buttarelli, A. Ciucci, G. Arduini, M.C. De Rosa, G. Scambia, D. Gallo, KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer, Journal of Experimental & Clinical Cancer Research 39(1) (2020) 265. ical Cancer Research (2020) 39:265. https://doi.org/10.1186/s13046-020-01775-9.
[53] R. Niu, Y. Tang, Y. Xi, D. Jiang, High Expression of Krüppel-like Factor 7 Indicates Unfavorable Clinical Outcomes in Patients with Lung Adenocarcinoma, The Journal of surgical research 250 (2020) 216-223. https://doi.org/ 10.1016/j.jss.2019.12.053.